Physician profile
Eric Vail
NPI 1609277649
$298,113.52
in general payments reported to CMS, 2019-2025
22 companies · $58K in 2025
The $58K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $23K · 2021: $27K · 2022: $37K · 2023: $33K · 2024: $79K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $73K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Travel and Lodging: $19K · Honoraria: $5,700 · Food and Beverage: $4,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $72,556.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,464.50 |
| Travel and Lodging | $18,730.78 |
| Honoraria | $5,700.00 |
| Food and Beverage | $4,001.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $119,631.01 | 2020-2025 | Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $90,334.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $25,707.45 | 2021-2025 | Lynparza, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $17,282.48 | 2022-2025 | Rybrevant, Erleada |
| Amgen INC. | $13,387.12 | 2022-2024 | Lumakras, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $8,901.19 | 2019-2025 | |
| Astrazeneca Uk Limited | $6,589.83 | 2024 | Lynparza |
| Life Technologies Corporation | $5,921.87 | 2019-2024 | |
| Pfizer INC. | $3,319.40 | 2023-2024 | |
| Partner Therapeutics, INC. | $2,475.00 | 2025 | Bizengri |
| Genzyme Corporation | $1,876.26 | 2023 | |
| Abbvie INC. | $675.00 | 2024 | |
| Roche Diagnostics Corporation | $591.38 | 2022-2024 | Cobas 6000 Core Unit, Avenio Millisect, Cobas Hbv/Hcv/Hiv-1 Control Kit |
| Oxford Gene Technology INC | $418.86 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $394.22 | 2024-2025 | Rybrevant |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Illumina, INC. | $190.25 | 2025 | Oncology Testing, Genetic Disease Testing |
| Pillar Biosciences, INC | $123.43 | 2024 | |
| Menarini Silicon Biosystems, INC. | $100.00 | 2023 | Cellsearch |
| Tempus Ai, INC | $70.31 | 2025 | Xt Cdx |
| Genentech USA, INC. | $55.10 | 2019 | |
| Stryker Corporation | $38.62 | 2023 | Stryker |
| Caris Mpi, INC. | $30.47 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.